Armata Pharmaceuticals (NYSE:ARMP) said its inhaled bacterial infection drug for lung disorder was well-tolerated with a treatment emergent adverse event (TEAE) profile similar to placebo in a phase ...
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage ...
Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage cocktail to improved outcomes in patients with bacteria in their blood, opening ...
The Armata is a new-generation tank. It is a clean sheet design with a number of advanced features. It has little in common ...
RedEffect Official on MSN
New evidence raises questions about the protection of the T-14 Armata
Recently released images and test data provide a closer look at the T-14 Armata’s armor layout, suggesting its protection may ...
Summary: The T-14 Armata tank, unveiled in 2015, was intended to be a revolutionary advancement in armored warfare. -Featuring an unmanned turret, advanced armor, and a new 125mm smoothbore cannon, it ...
A British Army intelligence report offers an alarmist assessment of Russia’s new T-14 Armata main battle tank. Most U.S. defense analysts, however, are much more measured in their analysis of the new ...
Armata Pharmaceuticals ( ARMP) announced Thursday that it has closed the second and final tranche of its previously announced private placement with Innoviva Strategic Opportunities, a wholly-owned ...
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It ...
The T-14 Armata is equipped with an unmanned turret and all the crew is located at the front of the hull. The new unmanned remote turret of Aramata T-14 would be equipped with a new generation of ...
"The completion of enrollment of our diSArm study is a significant milestone in the development of AP-SA02, moving us one step closer to introducing an effective new treatment option to patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback